MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

By Aaron J Schetter, S. Leung, Jane J. Sohn, Krista A. Zanetti, E. Bowman, N. Yanaihara, S. Yuen, T. Chan, D. Kwong, G. Au and 4 more. Journal of the American Medical Association (JAMA), 2008

1,665 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/76d64b5f9c1311b94b5902aa330286ec63599af9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

Reprogramming of miRNA networks in cancer and leukemia. (2010, neutral): “GSE8126 and GSE7055 (Ambs et al. 2008), GSE17155 (Fassan et al. 2009), GSE3467 (He et al. 2005), GSE7828 (Schetter et al. 2008), GSE6857 (Budhu et al. 2008), GSE16654 (Chin et al. 2009), and GSE14936 (Seike et al. 2009), and at ArrayExpress (www.ebi.ac.uk/microarray-as/ae) under accession nos.”
Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening (2009, methodology): “Furthermore, miRNA expression signatures have been used to predict prognosis.”
MicroRNAs and cancer: short RNAs go a long way. (2009, background): “Similarly, in colon cancers, elevated expression of miR-21 is associated with poor survival (Schetter et al., 2008), whereas in chronic lymphocytic leukemias an miRNA “signature” composed of 13 miRNAs is associ- 590 Cell 136, February 20, 2009 ©2009 Elsevier Inc. ated with disease progression…”
MicroRNAs in development and disease. (2011, background): “Expression profiling of tumors identified 37 miRNAs that are differentially expressed in CRC (536).”
MicroRNAs in body fluids—the mix of hormones and biomarkers (2011, neutral): “High miR-21 expression levels were associated with poor survival and therapeutic outcome in 84 patients with colon adenocarcinoma”
MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy (2011, neutral): “Among others, miR-21 levels were predictive of treatment response; high miR-21 levels correlated with poor therapeutic outcom”
Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma (2009, background): “For some of these tumors, an association of miRNA expression with clinical data and outcome was described.(4,10) To date, few articles investigated miRNA regulation in prostate cancer.”
Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer (2010, background): “Since these 2 circulating miRNAs are significantly elevated in cancer patients from the early stages of cancer and in relatively small tumors, it may be proposed as an early detection test for CRC. Normalization is a key step for the accurate quantification of RNA levels with qRT-PCR.”
STAT3 activation of miR-21 and miR-181b-1, via PTEN and CYLD, are part of the epigenetic switch linking inflammation to cancer (2010, background): “In accordance with previous work, RNA levels of STAT3 (Iliopoulos et al., 2009; Bromberg et al., 1999; Grivennikov et al., 2009), miR-21, and miR-181b-1 (Schetter et al., 2008; Yan et al., 2008; Cervigne et al., 2009) are often increased in cancer tissues relative to normal tissues.”